The COVID-2019 also known as Novel Coronavirus or SARS-CoV-2 outbreak has become the international health emergency. As it is increasing at a very faster rate and demand of the time is to have therapeutic approaches which can be used to manage this pandemic. Miguel Angel Martinez performed a minireview for the therapeutic compounds available for the management of COVID-2019. 

The previously characterized medicinal compounds to control SARS-CoV, 2003 and MERS-CoV, 2012 could be active against COVID-19. Remdesivir (GS-5734), a nucleotide analog which is currently in trials for Ebola virus infections is the most promising compound. This compound proved its efficacy in animal models by inhibits the replication of the MERS-CoV and SARS-CoV. Moreover, in SARS-CoV patients the combination of HIV-1 protease inhibitors, lopinavir/ritonavir, and interferon-beta (LPV/RTV-INFb) found efficacious. 

In the transgenic humanized mice model the remdesivir found to be more effective than LPV/RTV-INFb against MERS-CoV. The high mortality rates due to the SARS-CoV-2, SARS-CoV, MERS-CoV indicate that their pathogenesis can be attributed to the pro-inflammatory response. But it is not clear whether to target inflammatory state or not. This review was aimed to provide summary of therapeutic options available against COVID-19.